Page last updated: 2024-12-10
ee 581
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
EE 581: photosensitive azido derivative of tyrosine(3)-octreotide used to label the somatostatin receptor; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3036100 |
MeSH ID | M0200722 |
Synonyms (8)
Synonym |
---|
azidophenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-threonyl-cysteinyl-threonin-ol |
ee-581 |
141949-00-0 |
l-cysteinamide, 4-azido-d-phenylalanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (r-(r*,r*))- |
phe(n3)-cys-tyr-trp-lys-thr-cys-thr-ol |
ee 581 |
(2s)-2-[[(2r)-3-[(1ar)-1a,2-dihydrothiireno[2,3-b]indol-6b-yl]-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-(4-azidophenyl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-n-[(2s,3r)-1-[[(2r)-2-(1,3-dihydroxybutan-2-ylamino)-3- |
(2s)-2-((2r)-2-((s)-2-((s)-2-((r)-2-amino-3-(4-azidophenyl)propanamido)propanamido)-3-(4-hydroxyphenyl)propanamido)-3-((1ar)-1a,2-dihydro-6bh-thiireno[2,3-b]indol-6b-yl)propanamido)-n-((2s,3r)-1-((2r)-2-((1,3-dihydroxybutan-2-yl)amino)-3-mercaptopropanami |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia." | ( Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. Breslin, MJ; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Reiss, DR; Renger, JJ; Stevens, J; Tannenbaum, PL; Winrow, CJ, 2011) | 0.37 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Dosed orally Suvorexant significantly and dose-dependently reduced locomotor activity and promoted sleep in rats (10, 30, and 100 mg/kg), dogs (1 and 3 mg/kg), and rhesus monkeys (10 mg/kg)." | ( Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. Breslin, MJ; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Reiss, DR; Renger, JJ; Stevens, J; Tannenbaum, PL; Winrow, CJ, 2011) | 0.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (7.69) | 18.2507 |
2000's | 4 (30.77) | 29.6817 |
2010's | 8 (61.54) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.69%) | 6.00% |
Case Studies | 1 (7.69%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (84.62%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |